Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia | Zendy

John C. Byrd | Zendy; Richard R. Furman | Zendy; Steven Coutré | Zendy; Ian W. Flinn | Zendy; Jan A. Burger | Zendy; Kristie A. Blum | Zendy; Barbara Grant | Zendy; Jeff P. Sharman | Zendy; Morton Coleman | Zendy; William G. Wierda | Zendy; Jeffrey A. Jones | Zendy; Weiqiang Zhao | Zendy; Nyla A. Heerema | Zendy; Amy J. Johnson | Zendy; Juthamas Sukbuntherng | Zendy; Betty Chang | Zendy; Fong Clow | Zendy; Eric Hedrick | Zendy; Joseph J. Buggy | Zendy; Danelle F. James | Zendy; Susan O’Brien | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Author(s) -

John C. Byrd,

Richard R. Furman,

Steven Coutré,

Ian W. Flinn,

Jan A. Burger,

Kristie A. Blum,

Barbara Grant,

Jeff P. Sharman,

Morton Coleman,

William G. Wierda,

Jeffrey A. Jones,

Weiqiang Zhao,

Nyla A. Heerema,

Amy J. Johnson,

Juthamas Sukbuntherng,

Betty Chang,

Fong Clow,

Eric Hedrick,

Joseph J. Buggy,

Danelle F. James,

Susan O’Brien

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1215637

Subject(s) - ibrutinib , bruton's tyrosine kinase , chronic lymphocytic leukemia , medicine , cancer research , tyrosine kinase , lymphocytic infiltration , leukemia , immunology , receptor

The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research